{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:40Z","timestamp":1788174580480,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.seminhematol.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:53:26Z","timestamp":1744163606000},"page":"90-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Durot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Drandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signy","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie J.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0001","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/sonc.2003.50064","article-title":"Prognostic factors in symptomatic Waldenstrom's macroglobulinemia","volume":"30","author":"Merlini","year":"2003","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V83.10.2939.2939","article-title":"Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility","volume":"83","author":"Gobbi","year":"1994","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.001_bib0003","first-page":"4163","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Multicenter Study Research Support, Non-U.S. Gov't. Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0004","first-page":"41","article-title":"Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)","volume":"98","author":"Dhodapkar","year":"2001","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.04.001_bib0006","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.23.02066","article-title":"Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia","volume":"42","author":"Zanwar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.001_bib0007","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7024","article-title":"Diagnosis and Risk Stratification in Waldenstrom Macroglobulinemia","volume":"22","author":"Zanwar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101129","article-title":"Current approach to Waldenstrom macroglobulinemia","volume":"62","author":"Kapoor","year":"2023","journal-title":"Blood Rev"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0009","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Consensus Development Conference Review","volume":"30","author":"Kyle","year":"2003","journal-title":"Seminars in oncology"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.beha.2016.08.014","article-title":"Prognostic factors and indications for treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Kyle","year":"2016","journal-title":"Best practice & research Clinical haematology"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0011","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjh.15201","article-title":"Prevalence and survival of smouldering Waldenstr\u00f6m macroglobulinaemia in the United States","volume":"184","author":"Pophali","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.001_bib0012","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Research Support, Non-U.S. Gov't Validation Studies","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0013","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.17691","article-title":"Disease outcomes and biomarkers of progression in smouldering Waldenstrom macroglobulinaemia","volume":"195","author":"Zanwar","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00394","article-title":"Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.04.001_bib0015","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.001_bib0016","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Research Support, U.S. Gov't","volume":"102","author":"Kyle","year":"2003","journal-title":"P.H.S. Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.001_bib0017","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0018","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/sonc.2003.50051","article-title":"Asymptomatic Waldenstrom's macroglobulinemia","volume":"30","author":"Alexanian","year":"2003","journal-title":"Seminars in oncology"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1529-8027.2010.00278.x","article-title":"Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2013first revision. Guideline","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.04.001_bib0020","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2005.06.147","article-title":"Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom\u2019s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system","volume":"23","author":"Baldini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.001_bib0021","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","article-title":"Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstrom macroglobulinemia","volume":"23","author":"Wang","year":"2021","journal-title":"Neoplasia"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.04.001_bib0022","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.001_bib0023","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.16086","volume":"187","author":"Varettoni","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.001_bib0024","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.16085","article-title":"The MYD88(L265P) conundrum in IgM monoclonal gammopathy of undetermined significance","volume":"187","author":"Kapoor","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.001_bib0025","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2021004926","article-title":"Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstrom macroglobulinemia","volume":"6","author":"Tahri","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70029","article-title":"Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry","volume":"8","author":"Moreno","year":"2024","journal-title":"Hemasphere"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.18502","article-title":"Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia","volume":"200","author":"Moreno","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.001_bib0028","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.001_bib0029","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/10428194.2019.1689393","article-title":"Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenstrom macroglobulinemia","volume":"61","author":"Merli","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0030","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ajh.26807","article-title":"Survival trends in young patients with Waldenstr\u00f6m macroglobulinemia: Over five decades of experience","volume":"98","author":"Chohan","year":"2023","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0031","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1182\/blood-2024-211664","article-title":"Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom's Macroglobulinemia (WM)","volume":"144","author":"Hunter","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.001_bib0032","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1080\/10428194.2020.1789625","article-title":"Predictors of short-term survival in Waldenstrom Macroglobulinemia","volume":"61","author":"Ruan","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-142884","article-title":"Waldenstr\u00f6m Macroglobulinemia in the Very Elderly (\u226575 years):Clinical Characteristics and Outcomes","volume":"136","author":"Zanwar","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0034","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.001_bib0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjh.17926","article-title":"Conditional relative survival in Waldenstrom's macroglobulinaemia: a population-based study in The Netherlands","volume":"196","author":"Amaador","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.001_bib0036","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.leukres.2010.04.005","article-title":"Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)","volume":"34","author":"Kastritis","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0037","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3816\/CLML.2011.n.028","article-title":"Prognostication of the high-risk WM patient","volume":"11","author":"Kastritis","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0038","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.001_bib0039","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41375-024-02156-3","article-title":"Circulating tumor cells in Waldenstrom macroglobulinemia","volume":"38","author":"Boccon-Gibod","year":"2024","journal-title":"Leukemia"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.001_bib0040","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Research Support, Non-U.S. Gov't","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0041","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3324\/haematol.2020.262899","article-title":"A prognostic index predicting survival in transformed Waldenstr\u00f6m macroglobulinemia","volume":"106","author":"Durot","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0042","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.25697","article-title":"Impact of MYD88(L265P) mutation status on histological transformation of Waldenstr\u00f6m Macroglobulinemia","volume":"95","author":"Zanwar","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0043","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","article-title":"Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia","volume":"33","author":"Zanwar","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0044","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-015-0172-y","article-title":"Waldenstrom macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis","volume":"8","author":"Cao","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0045","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.04.001_bib0046","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022017235","article-title":"How I use genomics and BTK inhibitors in the treatment of Waldenstrom macroglobulinemia","volume":"143","author":"Treon","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0047","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia and Its Impact on Treatment Strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.001_bib0048","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells. Research Support, Non-U.S. Gov't","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0049","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11899-024-00731-0","article-title":"Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenstrom Macroglobulinemia","volume":"19","author":"Tawfiq","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.001_bib0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, Signaling, and Treatment of Waldenstrom Macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0051","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m's Macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.04.001_bib0052","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"Roccaro","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0053","article-title":"Current approach to Waldenstrom Macroglobulinemia","volume":"31","author":"Ravi","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.04.001_bib0054","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood-2018-07-863241","article-title":"Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients","volume":"132","author":"Sklavenitis-Pistofidis","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.001_bib0055","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","article-title":"Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.04.001_bib0056","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood.V100.8.2996","article-title":"Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S","volume":"100","author":"Schop","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.001_bib0057","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.001_bib0058","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2018.190181","article-title":"MYD88 mutated and wild-type Waldenstrom's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4","volume":"103","author":"Guerrera","year":"2018","journal-title":"Haematologica"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.04.001_bib0059","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","article-title":"The cellular origin and malignant transformation of Waldenstrom macroglobulinemia. Research Support, Non-U.S. Gov't","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-319-40320-5_16","article-title":"Waldenstrom macroglobulinemia: genomic aberrations and treatment","author":"Kapoor","year":"2016","journal-title":"Plasma Cell Dyscrasias"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.001_bib0061","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.17028","article-title":"6q deletion in Waldenstr\u00f6m macroglobulinaemia negatively affects time to transformation and survival","volume":"192","author":"Garc\u00eda-Sanz","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0062","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2006.06389.x","article-title":"6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't","volume":"136","author":"Ocio","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0063","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3324\/haematol.2022.281053","article-title":"Inflammation in Waldenstrom macroglobulinemia is associated with 6q deletion and need for treatment initiation","volume":"107","author":"Forgeard","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0064","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.04.001_bib0065","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/bloodadvances.2019000635","article-title":"CXCR4(S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenstrom macroglobulinemia","volume":"3","author":"Gustine","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0066","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/01.HS9.0000847504.29146.b9","article-title":"A multicenter, International collaborative study evaluating frontline therapy with bendamustine rituximab Waldenstrom macroglobulinemia","author":"Zanwar","year":"2022","journal-title":"Abstract Hemasphere"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.04.001_bib0067","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1158\/1078-0432.CCR-23-3939","article-title":"Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenstrom Macroglobulinemia","volume":"30","author":"Yan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0068","first-page":"90","article-title":"Report of Consensus Panel 3 from the 11th International workshop on Waldenstr\u00f6m's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenstr\u00f6m's Macroglobulinemia","volume":"60","author":"Garcia-Sanz","year":"2023"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0069","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.001_bib0070","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0071","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study","author":"Dimopoulos","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2025.04.001_bib0072","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/01.HS9.0000847504.29146.b9","article-title":"A multicenter, international collaborative study evaluating frontline therapy with bendamustine rituximab for Waldenstrom macroglobulinemia","volume":"6","author":"Zanwar","year":"2022","journal-title":"Abstract Hemasphere"},{"issue":"33","key":"10.1053\/j.seminhematol.2025.04.001_bib0073","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.04.001_bib0074","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for waldenstr\u00f6m's macroglobulinemia: a prospectively randomized trial of the european consortium for waldenstr\u00f6m's macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl_1","key":"10.1053\/j.seminhematol.2025.04.001_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0076","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-09-806463","article-title":"First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival","volume":"131","author":"Pika","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.001_bib0077","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0078","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstr\u00f6m's Macroglobulinemia: Final Analysis of the Phase I\/II HOVON124\/ECWM-R2 Study","volume":"40","author":"Kersten","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0079","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood-2023-187237","article-title":"Outcomes of Patients with Relapsed\/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis","volume":"142","author":"Sawalha","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstrom Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10277","key":"10.1053\/j.seminhematol.2025.04.001_bib0081","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"The Lancet"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0082","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed \/Refractory Waldenstr\u00f6m Macroglobulinemia: Results from the Phase 1\/2 BRUIN Study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2015.11.461","article-title":"Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenstr\u00f6m Macroglobulinemia (WM)","volume":"22","author":"Paludo","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0084","series-title":"Report of Consensus Panel 6 from the 11th International Workshop on Waldenstr\u00f6m's Macroglobulinemia on Management of Waldenstr\u00f6m's Macroglobulinemia Related Amyloidosis","author":"Merlini","year":"2023"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0085","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.bbmt.2018.12.003","article-title":"Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis","volume":"25","author":"Sidiqi","year":"2019","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.04.001_bib0086","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Comment Multicenter Study","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0087","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2024-197901","article-title":"Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenstr\u00f6m's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)","volume":"144","author":"Kyriakou","year":"2024","journal-title":"Blood"},{"issue":"33","key":"10.1053\/j.seminhematol.2025.04.001_bib0088","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0089","first-page":"4404","article-title":"A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"144","author":"Castillo","year":"2024","journal-title":"Abstract Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0090","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2021-152682","article-title":"CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial","volume":"138","author":"Ailawadhi","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0091","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/10428194.2021.2005045","article-title":"Plamotamab (XmAb((R))13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstrom macroglobulinemia","volume":"63","author":"Parrondo","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0092","first-page":"3011","article-title":"A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenstr\u00f6m Macroglobulinemia: An Interim Analysis","volume":"144","author":"Castillo","year":"2024","journal-title":"Abstract Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.04.001_bib0093","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-136440","article-title":"Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"136","author":"Shadman","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0094","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminhematol.2023.03.006","article-title":"Report of consensus panel 7 from the 11th international workshop on Waldenstrom macroglobulinemia on priorities for novel clinical trials","volume":"60","author":"Tam","year":"2023","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0165-4608(01)00526-X","article-title":"Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression","volume":"132","author":"Schop","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0096","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/sj.leu.2403369","article-title":"Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases","volume":"18","author":"Chang","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0097","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.18632\/oncotarget.23261","article-title":"Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders","volume":"9","author":"Yi","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0098","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bjh.13091","article-title":"Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. Comment Letter","volume":"168","author":"Varettoni","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0099","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3816\/CLM.2009.n.013","article-title":"Assessment of bone marrow response in Waldenstrom's macroglobulinemia","volume":"9","author":"Varghese","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hon.3082","article-title":"Molecular remission is an independent predictor of progression-free survival in patients with Waldenstrom macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study","volume":"41","author":"Varettoni","year":"2023","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clml.2013.03.001","article-title":"Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenstrom macroglobulinemia","volume":"13","author":"Uljon","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0102","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.23880","article-title":"Extramedullary Waldenstrom macroglobulinemia","volume":"90","author":"Banwait","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0103","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/jha2.1037","article-title":"Extramedullary disease in Waldenstrom macroglobulinemia: A population-based observational study","volume":"5","author":"Ostergaard","year":"2024","journal-title":"EJHaem"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.001_bib0104","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.14881","article-title":"Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)","volume":"179","author":"Durot","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.001_bib0106","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41375-024-02393-6","article-title":"The clinical impact of acquired von Willebrand syndrome secondary to Waldenstrom macroglobulinemia: an underrecognized source of major bleeding events","volume":"38","author":"Chohan","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.04.001_bib0107","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1080\/10428194.2023.2214026","article-title":"Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenstrom macroglobulinemia","volume":"64","author":"Zanwar","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3324\/haematol.2016.147728","article-title":"Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome","volume":"102","author":"Minnema","year":"2017","journal-title":"Haematologica"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.04.001_bib0109","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia. Clinical Trial Multicenter Study Research Support, Non-U.S. Gov't","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.04.001_bib0111","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.001_bib0112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0113","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.04.001_bib0114","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"27","key":"10.1053\/j.seminhematol.2025.04.001_bib0115","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.001_bib0116","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.001_bib0117","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.001_bib0118","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/cas.15344","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia","volume":"113","author":"Sekiguchi","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.04.001_bib0120","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.04.001_bib0121","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.04.001_bib0122","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3490","article-title":"Zanubrutinib plus Ixazomib and Dexamethasone in newly diagnosed symptomatic Waldenstr\u00f6m macroglobulinemia:a phase II study","author":"Xiong","year":"2025","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.001_bib0123","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/bjh.19320","article-title":"A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia","volume":"204","author":"Parrondo","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:22:49Z","timestamp":1750857769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0037196325000113"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}